Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Plos One|September 14, 2023
Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)Karen Leroy, Clarisse Audigier Valette, Jérôme Alexandre, et al.
The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2025
Clinical characteristics and management of long survivors in extensive stage small cell lung cancerElisa Gobbini, Mamadou Hassimiou Diallo, David Pasquier, et al.
British Journal of Cancer|February 12, 2019
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trialElodie Maille, Solenn Brosseau, Vincent Hanoux, et al.
Clinical Lung Cancer|July 8, 2019
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS CohortSolenn Brosseau, Claire Danel, Arnaud Scherpereel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2019
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III TrialGuillaume Eberst, Amélie Anota, Arnaud Scherpereel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTEMarie Wislez, Fabrice Barlesi, Benjamin Besse, et al.
Lung Cancer (Amsterdam, Netherlands)|July 7, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trialOlivier Bylicki, Florian Guisier, Arnaud Scherpereel, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDSElisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Pageof 9